Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116786 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 15
- Study locations
NCT06116786: Recruiting Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Johnson & Johnson Enterprise Innovation.
NCT06116786 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 126 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower). The trial reports 15 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06116786, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-thre
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Cetrelimab
- DRUG JNJ-86974680
Study Locations (15)
Other
- Charite Research Organisation GmbH - Berlin
- Universitaetsklinikum Giessen und Marburg GmbH - Giessen
- Severance Hospital Yonsei University Health System - Seoul
- Samsung Medical Center - Seoul
- Hosp. Univ. Quiron Dexeus - Barcelona
- Hosp Univ Vall D Hebron - Barcelona
- Hosp. Univ. 12 de Octubre - Madrid
- Hosp. Univ. I Politecni La Fe - Valencia
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Herbert Irving Comprehensive Cancer Center Columbia University Medical Center - New York
Georgia
- City of Hope - Newnan
New Jersey
- Hackensack University Medical Center - Hackensack
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Virginia
- Next Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2029-06-07 |
| Phase | Phase 1 |
What NCT06116786 shows while recruiting
NCT06116786 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT06116786 lists 15 locations in 7 states (Other, New York, Georgia).
Frequently Asked Questions
What is clinical trial NCT06116786 about?
NCT06116786 is a clinical study titled "A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer". The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy.
What is the current status of trial NCT06116786?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2023-11-27. Estimated completion is 2029-06-07.
What conditions does trial NCT06116786 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT06116786?
The interventions under investigation include: Radiation Therapy (RADIATION), Cetrelimab (DRUG), JNJ-86974680 (DRUG).
Who is sponsoring clinical trial NCT06116786?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116786 being conducted?
This trial has 15 study locations across Georgia, New Jersey, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06116786's enrollment target sits among peer trials
126 65th of 130 higher than 65 of 130 other Carcinoma, Non-Small Cell Lung trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Non-Small Cell Lung trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
RECRUITING · Phase 1
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI